Roswell Park has transformed a 150-year-old residence at 907 Michigan Ave., blending history and vision into a welcoming new home for its community outreach: the Roswell Park Community Outreach & Engagement Center. Roswell Park team members, patients, advocates and community leaders gathered for a grand opening of the renovated and expanded space.

Gov. Kathy Hochul announced that New York's first cell and gene therapy hub will be housed at Roswell Park. The $98 million center will help to support the research and development of life-saving therapies at Roswell, significantly grow its well-established research capabilities, and establish Roswell as one of the premier cell therapy discovery and production institutions in the nation.

A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The designation awarded to MimiVax Inc. provides more extensive and accelerated access to FDA resources for the company’s development of the novel cancer immunotherapy SurVaxM, which is now in late-stage trials around the country.

While most patients treated with radiation therapy for cancers of the head and neck develop oral mucositis, there is no standard approach for monitoring those patients for this often-debilitating side effect of cancer treatment or for measuring its severity. In new work published today by JAMA Network Open, a research team at Roswell Park Comprehensive Cancer Center shows that more patients than previously thought experience mucositis and can benefit from earlier diagnosis and intervention to address its effects.